Nearly one in five American adults experience some form of mental illness in any given year. In addition, the National Institute of Mental Health (NIMH) estimates that 20 percent of children ages 13 to 18 in the United States either currently or at some point had a mental illness.
As science continues to advance, America’s biopharmaceutical companies are working to develop medicines that help reduce these diseases into manageable conditions. Researchers are studying biomarkers and the ways current medicines impact the pathology and workings of the brain. This research has helped produce 145 medicines that are in development to help the more than 40 million Americans living with a mental illness. These potential treatments could help manage symptoms of schizophrenia, anxiety-disorders, attention-deficit disorders, substance abuse and depression.